Shizuoka, Japan

Shigeyuki Iijima

USPTO Granted Patents = 6 



Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 52(Granted Patents)


Location History:

  • Gotenba, JP (2012 - 2014)
  • Shizuoka, JP (2011 - 2018)

Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Shigeyuki Iijima: Innovator in Antibody Development

Introduction

Shigeyuki Iijima is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of six patents to his name, Iijima's work has the potential to impact cancer therapies significantly.

Latest Patents

One of Iijima's latest patents involves an anti-glypican-3 antibody. This antibody comprises one or more amino acid substitutions introduced in the Fc region. Specifically, the invention highlights that one or more amino acid residues at positions 239, 298, 326, 330, and 332 in the Fc region can be substituted with other amino acid residues. The Fc-modified anti-glypican-3 antibody exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, making it useful in treating various cancers, including hepatic cancer. Additionally, the patent discloses an anticancer agent that includes the anti-glypican-3 antibody and a pharmaceutically acceptable carrier, along with a method for treating cancer patients using this agent.

Career Highlights

Throughout his career, Shigeyuki Iijima has worked with notable companies in the biotechnology sector. He has been associated with Chugai Seiyaku Kabushiki Kaisha and Xencor, Inc., where he has contributed to innovative research and development projects. His expertise in antibody engineering has positioned him as a key figure in the field.

Collaborations

Iijima has collaborated with several professionals in his field, including Izumi Sugo and Masayuki Tsuchiya. These collaborations have likely enhanced his research and development efforts, leading to significant advancements in antibody therapies.

Conclusion

Shigeyuki Iijima's work in developing innovative antibodies showcases his commitment to advancing cancer treatment. His patents reflect a deep understanding of biotechnology and a dedication to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…